olema.comCrawled Nov 8, 2026
Olema Oncology conducts clinical trials for therapies in metastatic breast cancer and other endocrine-driven cancers.
Olema Oncology advances science focused on endocrine-driven cancers, nuclear receptors, and mechanisms of resistance to improve patient outcomes.
Olema Oncology’s clinical pipeline includes therapies targeting metastatic breast cancer and improving patient outcomes.
Olema Oncology publishes research on endocrine-driven cancers, nuclear receptors, and oncology drug discovery.
Olema Oncology lists open positions supporting oncology research and drug development.
Olema Oncology’s leadership team oversees research, drug development, and clinical strategy in breast cancer and oncology.
Olema Oncology is a clinical-stage biopharmaceutical company developing therapies for breast cancer using expertise in endocrine-driven cancers.
Olema Oncology can be contacted in San Francisco or Cambridge for inquiries about research, clinical programs, partnerships, or careers.
Olema Oncology is a clinical-stage biopharmaceutical company developing novel therapies to transform treatment for metastatic breast cancer and beyond.
Olema Oncology presents clinical data from its **Phase 1b/2 study of OP-3136 combined with fulvestrant** and **Phase 1b/2 study of palazestrant combined with everolimus** at the 2026 San Antonio Breast Cancer Symposium. The company also shares findings from its **Phase 1b study of palazestrant** alone. These presentations highlight ongoing efforts to evaluate targeted therapy combinations for breast cancer treatment.
Nov 2026BioSpaceNews article
Olema Oncology reports first-quarter 2026 financial and operating results, covering the period ending March 31. The clinical-stage biopharmaceutical company specializes in targeted therapies for breast cancer and other indications. This update follows its Nasdaq-listed status under the ticker **OLMA**.
May 2026BioSpaceNews article
Olema Oncology reports its fourth-quarter and full-year 2025 financial and operating results, covering its clinical-stage targeted therapies for breast cancer and other indications. The company, listed on Nasdaq under the ticker **OLMA**, provides updates on its development pipeline and financial performance for the period ending December 31, 2025.
Mar 2026BioSpaceNews article
Pfizer’s palazestrant, a selective estrogen receptor degrader (SERD), enters Phase 3 trials as a monotherapy for treating **ER-positive, HER2-negative breast cancer**. The trial follows earlier clinical data showing potential efficacy in this patient subgroup. Researchers aim to further assess its safety and effectiveness in advanced or metastatic settings.
Dec 2025onclive.comNews article
